Chronic kidney disease (CKD) affects an estimated 350 million people worldwide. CKD is a progressive disease with large unmet medical needs, and growing in prevalence due to the epidemic of type 2 diabetes.
Vidasym has two innovative programs for CKD: a series of novel vitamin D receptor modulators (VDRMs), and non-absorbed, calcium-free, aluminum-free, highly effective phosphate binders derived from natural plant polymer. There are on-market products in both categories with their limitations well understood. The advantages of Vidasym's candidate molecules are clearly defined.
Vidasym has also identified several VDR drug candidates for additional pharmaceutical markets, such as cancer-related thrombosis, osteoporosis and psoriasis.